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Key Words: human placenta RT-PCR GESTATIONAL DIABETES IS ONE OF THE MOST prevalent medical complications of pregnancy. Between 1 and 5% of pregnant women display abnormalities in glucose metabolism.
In Germany, however, only 10% of these women are diagnosed with gestational diabetes by the current risk-screening measures (1) . Gestational diabetes causes increased fetal wastage such as macrosomia, fetal retardation, edema, and multiple metabolic effects. Investigation of placentas from diabetic mothers demonstrate plethora, chorangiosis, edema, and a relatively immature villous structure (2-7), which lead to chronic disturbances in intervillous circulation and dilatation of capillanes (8, 9).
As a vasodilator, nitric oxide (NO)2 is involved in regulation of vascular tone. In the fetoplacental circulation, NO apparently serves to maintain basal tone as well to attenuate the action of vasoconstrictors (10) . However, abnormal levels of NO may contribute to maternal disorders (11) . Furthermore, increased blood flow and vascular permeability in early diabetes have been associated with increased NO generation via inducible nitric oxide synthase (iNOS; E.C. 1.14.13.39) (12) . Characteristically, vasodilatation and increased blood flow are early vascular responses to acute hyperglycemia and increased insulin levels (12, 13 
METHODS
Cestational diabetes was diagnosed by routine blood glucose sampling during outpatient care throughout the pregnancy by using hemo-cue b-glticose system, which uses the glucose-dehydrogenase method in a microcuvette system. For blood glucose values higher than 120 mgldl, a 75 g oral glucose tolerance test (oGT'F) was performed for evaluation of gestational diabetes according to the National Diabetes Data Group criteria (30) . Test results in which two or more values were elevated were considered abnormal. Patients received a comprehensive education program, instructions for daily multiple self-monitoring of capillary whole-blood glucose levels, and an individual dietary regimen with 30-35 kcallkg ideal body weight in combination with or without insulin treatment ( Table  1) . As soon as the patient was hospitalized, diurnal and nocturnal measurement of fasting, pre-, and postprandial blood glucose levels was performed.
Patients were treated to attain fasting blood glucose levels between 3.3 and 4.4 mmol/l and a 2 h postprandial value between 5.6 and 6.6 mmol/l. If blood glucose levels could not be maintained normoglycemic by diet, appropriate insulin treatment was administered.
After elective caesarean section or spontaneous uncomplicated vaginal delivery, placentas from healthy women (n 10) and from patients with gestational diabetes (n8)
were obtained (Table 1 and Table 2 ) from the Department of Obstetrics of the Benjamin Franklin Hospital, rinsed three times with 0.9% saline, and immediately frozen in liquid nitrogen. Placental tissue was microscopically and macroscopically investigated by a pathologist, and placentas with signs of inflammation were excluded from investigation.
Tissue collection was performed following the standard guidelines set by the ethics committee of the Benjamin Franklin University Hospital, Freie Universii#{228}t Berlin.
Isolation of total RNA and reverse-transcription-polymerase chain reaction (RT-PCR)
Total cellular RNA was isolated from placental tissues by using TRIZOL Reagent (Gibco BRL, Eggenstein, Germany) according to the manufac- s, followed by an additional 6 mm extension period at 72#{176}C. PCR for iNOS was carried out in a total volume of 50 JIl containing 5 J.il of RT in 50 JJJ lOx buffer (Gibco BRL), 1.5 mM MgCI2, 0.4 mM dNTPs, 0.1 tM of each specific primer, DEPC-treated water, and 2.5 U Taq polymerase (Gibco BRL). The PCR temperature profile for iNOS cDNA consisted of 33 cycles at 94#{176}C for 30 s, 61#{176}C for 1 mm, and 72#{176}C for 30 s, followed by an additional 6 mm extension period at 72#{176}C using the following primers:
5'-GCAGAATGTGACCATCATGG-3' (sense; position: 1490-1509) and 5'-ACAACCTT'GGIGTI'GAAGGC-3' (antisense; position:
1915-18)6). Control reactions for RT and PCR were performed by using water instead of mRNA or cDNA in reaction mixtures. The presence and size of the obtained PCR products were analyzed on ethidium bromide-stained agarose gels (2%). The specificity of the obtained iNOS PCR product was checked by digesting the amplificate with two specific restriction enzymes (Stu I and Ava I).
Protein preparation
Placental tissue samples were thawed in 3 ml ice-cold washing buffer (50 mM Tris, 2 mM EDTA, 150 mM NaC1, 0.5 mM D'VF, pH 7.5) per 1 g tissue wet weight and homogenized on ice in 2.5 ml homogenization buffer (50 mM Tris pH 7.4, 0.2 mM EDTA, 0.5 mM Dl'!', 1 j.tM pepstatin A, 100 JIM phenylmethylsulfonyl fluoride, 2 jiM leupeptmn) per 1 g tissue wet weight using a Potter-Elvehjem Teflon glass tissue homogenizer (10 strokes; B. Braun, Melsungen, Germany). All subsequent procedures were performed at 4#{176}C. Homogenates were centrifuged at 15,000 x g for 30 mm. The resulting supernatants were retained for further experiments.
Protein concentrations were detennined in triplicate according to Bradford (31) using bovine serum albumin (BSA) as a reference standard.
SDS-PAGE and Western blotting
Total cellular placental homogenates containing 10 Jig protein as well as lysate from y-IFN-and LPS-activated mouse macrophages as positive controls were diluted (1:4) in sodium dodecyl sulfate (SDS) sample buffer according to Laemmli (32) (0.5 M Tris-HCI pH 6.8, 10% (v/v) glycerol, 10% (w/v) SDS, 5% (v/v) (-mercaptoethanol, 0.05% (w/v) bromphenol blue) and heated at 95#{176}C for 4 mm. Products were separated by SDS-PAGE using 10% gels and then electroblotted to nitrocellulose membranes using a wet blot transfer method at constant voltage settings (100 V. 1 h). The quality of protein blots was determined by Ponceau S staining of nitrocellulose.
BSA (5% w/v) -blocked nitrocellulose membranes (1 h, room temperature)
were washed twice in 0.1% Tween-2O Tris-buffered saline (1TBS), pH 7.5, for 5 mm, rinsed twice for 5 mm in Iris-buffered saline (TBS), pH 7.5, and subsequently incubated overnight with lgG2a-monoclonal antibody against iNOS (AF-FINETI Research, Nottingham, U.K.) at a 1:500 dilution. After washing in TTBS and TBS, blots were incubated for 1 h with anti-mouse IgGconjugated alkaline-phosphatase antibody at a 1:5000 dilution (Dakopatts, Hamburg, Germany). Blots were finally rinsed with TTBS and TBS, and immune complexes were visualized by staining for alkalinephosphatase activity.
Immunohistochemistry
Cryostat sections (4 JIm thick) of placental tissue from healthy women and patients with gestational diabetes were cut at -25#{176}C with a Reichert Jung ciyostat (Heidelberg, Germany), mounted onto chrome alum-gelatinized glass slides, air-dried for 1 h, pretreated with acetone for 10 mm at -25#{176}C, and, finally, air-dried for 10 mm. Section The FASEB Journal SCHONFELDER EF AL.
RESULTS
RT-PCR analysis
RT-PCR analysis revealed expression of iNOS mRNA in placental tissue obtained from patients with gestational diabetes (lanes 2-5; Fig. lA) . In contrast, iNOS mRNA was not detectable in placentas from healthy women (lanes 6-9; Fig. 1A) . Figure  1A represents a typical analysis of PCR products by gel electrophoresis, resulting in bands of the predicted size of 426 bp in lanes 2-5 (gestational diabetes) but not in lanes 6-9 (controls). Therefore, iNOS mRNA appears to be expressed exclusively in placentas of patients with gestational diabetes. Restriction analysis of the iNOS PCR product by Stu I or Ava I revealed fragments of the predicted size of 200 and 226 bp for Stu I, and 321 and 105 bp for Ava I. Thus, the identity of the expected iNOS fragment was confirmed.
RT-PCR analysis of GAPDH mRNA expression in pla- false positive iNOS mRNA detection from genomic DNA can be excluded.
Furthermore, compared to similar levels of the housekeeping gene GAPDH, the levels of iNOS gene expression appeared to vary among placentas from patients with gestational diabetes (Fig. 1A, B) .
Western blot analysis
The presence of iNOS protein expression in patients with gestational diabetes was investigated by Western blot analysis.
A representative Western blot analysis of protein from placentas of healthy women (lanes 1-3) and from one patient with gestational diabetes (lane 4) is shown in Fig. 2A using monoclonal antibodies against iNOS. A single band at the predicted molecular mass of 130 ±1 kDa was detected only in protein samples from patients with gestational diabetes, but not from healthy women (Table 3 ). In healthy women we could only detect a single band of 159 kDa in lane 2 of Fig. 2A , perhaps corresponding to unspecific staining of an unknown protein.
Furthermore, Western blot analysis of placental protein from patients with gestational diabetes and control of y-IFN-and LPS-treated mouse macrophages revealed single iNOS protein bands of identical apparent molecular mass of 130 ±1 kDa (Fig. 2B) .
Immunohistochemistry
Immunostaining for human macrophages (clone: Ber-MAC3) (33) was performed with cryosectioris of placental tissue and revealed no immunoreactivity in placental tissue in either group of women, even though immunoreactivity could be detected in activated macrophages of the human tonsils as positive control reactions.
Immunostaining for iNOS was performed with cryosections of placental tissue from healthy women (Fig. 3) and from patients with gestational diabetes (Fig. 4) using two different antibodies against iNOS. Both antibodies revealed identical cell-specific immunoreactivity, but polyclonal antibodies demonstrated more intense immunoreactivity. Polyclonal and monoclonal antibodies against iNOS revealed no immunoreactivity in the placental tissue of healthy women (Fig. 3) . In contrast, immunoreactivity was localized to placental villi of patients with gestational diabetes with intense immunoreactivity in trophoblasts of placental stem villous ( Fig. 4 ; using polyclonal antibody against ble for NO generation in the human placental villous tree (20) (21) (22) (23) (24) (25) (26) (27) .
Measurement of NOS enzyme activity in human primordial placenta has demonstrated only eNOS activity (29) .
The major finding in the present study is that human placental villi appear to express the calcium-independent iNOS under pathophysiological conditions ( In contrast to the findings of Conrad, Garvey, and Kukor (22, 24, 29) , who observed that only eNOS is expressed in human placenta and that it contributes to the control of blood flow in the placenta circulation, we suggest that in pathophysiological conditions iNOS expression can be induced in human placenta and might play an important role in pathological influence on blood flow and cellular defense.
